84 related articles for article (PubMed ID: 21145375)
21. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of HPV 16, 18 vaccination in Brazil.
Goldie SJ; Kim JJ; Kobus K; Goldhaber-Fiebert JD; Salomon J; O'shea MK; Xavier Bosch F; de Sanjosé S; Franco EL
Vaccine; 2007 Aug; 25(33):6257-70. PubMed ID: 17606315
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy and safety of vaccines against human papillomavirus (HPV)].
Prygiel M; Janaszek-Seydlitz W
Przegl Epidemiol; 2012; 66(4):657-65. PubMed ID: 23484396
[TBL] [Abstract][Full Text] [Related]
24. HPV vaccines: what remains to be done? Interview by Lauren Constable.
Zur Hausen H
Expert Rev Vaccines; 2011 Nov; 10(11):1505-7. PubMed ID: 22043949
[No Abstract] [Full Text] [Related]
25. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
Arbyn M; Dillner J
J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
[TBL] [Abstract][Full Text] [Related]
26. [Cervical carcinoma and the vaccination experience with Cervarix].
Berberova M
Akush Ginekol (Sofiia); 2012; 51 Suppl 1():4-5. PubMed ID: 23236670
[No Abstract] [Full Text] [Related]
27. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
28. Vaccination against human papillomavirus.
BMJ Group
Drug Ther Bull; 2008 Dec; 46(12):89-93. PubMed ID: 19056700
[TBL] [Abstract][Full Text] [Related]
29. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing.
Schiffman M
Cancer; 2007 Jun; 111(3):145-53. PubMed ID: 17487850
[TBL] [Abstract][Full Text] [Related]
30. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up.
Roteli-Martins CM; Naud P; De Borba P; Teixeira JC; De Carvalho NS; Zahaf T; Sanchez N; Geeraerts B; Descamps D
Hum Vaccin Immunother; 2012 Mar; 8(3):390-7. PubMed ID: 22327492
[TBL] [Abstract][Full Text] [Related]
31. "Is cancer contagious?": Australian adolescent girls and their parents: making the most of limited information about HPV and HPV vaccination.
Cooper Robbins SC; Bernard D; McCaffery K; Brotherton J; Garland S; Skinner SR
Vaccine; 2010 Apr; 28(19):3398-408. PubMed ID: 20199758
[TBL] [Abstract][Full Text] [Related]
32. Quantifying the impact of dissimilar HPV vaccination uptake among Manitoban school girls by ethnicity using a transmission dynamic model.
Shafer LA; Jeffrey I; Elias B; Shearer B; Canfell K; Kliewer E
Vaccine; 2013 Oct; 31(42):4848-55. PubMed ID: 23933332
[TBL] [Abstract][Full Text] [Related]
33. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.
Boot HJ; Wallenburg I; de Melker HE; Mangen MJ; Gerritsen AA; van der Maas NA; Berkhof J; Meijer CJ; Kimman TG
Vaccine; 2007 Aug; 25(33):6245-56. PubMed ID: 17630049
[TBL] [Abstract][Full Text] [Related]
34. Adolescents' awareness of HPV infections and attitudes towards HPV vaccination 3 years following the introduction of the HPV vaccine in Hungary.
Marek E; Dergez T; Rebek-Nagy G; Kricskovics A; Kovacs K; Bozsa S; Kiss I; Ember I; Gocze P
Vaccine; 2011 Nov; 29(47):8591-8. PubMed ID: 21939711
[TBL] [Abstract][Full Text] [Related]
35. Quadrivalent human papillomavirus vaccine.
Barr E; Tamms G
Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
[TBL] [Abstract][Full Text] [Related]
36. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.
Julius JM; Ramondeta L; Tipton KA; Lal LS; Schneider K; Smith JA
Pharmacotherapy; 2011 Mar; 31(3):280-97. PubMed ID: 21361739
[TBL] [Abstract][Full Text] [Related]
37. [Implementation of HPV vaccination in Germany].
Schreckenberger C; Kaufmann AM; Schneider A
Dtsch Med Wochenschr; 2007 Oct; 132(42):2221-4. PubMed ID: 17926251
[No Abstract] [Full Text] [Related]
38. [Vaccination against HPV in adults].
Gil Á
Rev Esp Quimioter; 2009 Nov; 22 Suppl 1():22-5. PubMed ID: 20084345
[No Abstract] [Full Text] [Related]
39. [Demyelinating disease and vaccination of the human papillomavirus].
Álvarez-Soria MJ; Hernández-González A; Carrasco-García de León S; del Real-Francia MÁ; Gallardo-Alcañiz MJ; López-Gómez JL
Rev Neurol; 2011 Apr; 52(8):472-6. PubMed ID: 21425100
[TBL] [Abstract][Full Text] [Related]
40. Are we missing an opportunity for cancer prevention? Human papillomavirus vaccination for survivors of pediatric and young adult cancers.
Temkin SM; Seibel NL
Cancer; 2015 Oct; 121(19):3395-402. PubMed ID: 26110510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
